The earnings call reflects a mix of strong prescription growth and financial improvements, offset by operational and adherence challenges impacting Vafseo's rollout. While revenue and patient access have grown significantly, the company faces hurdles in addressing logistics and adherence issues to sustain this growth.

Company Guidance

During the third quarter of 2025, Akebia highlighted several key metrics and strategic developments in their financial results conference call. Vafseo, their lead product for treating anemia in dialysis patients, generated $14.3 million in revenue, with more total prescriptions in its first 41 weeks of launch than any recent dialysis launch. The company expanded accessible patient numbers from 40,000 to almost 70,000 by the end of Q3, significantly increasing prescribing access to over 260,000 patients. This growth was bolstered by a successful DaVita pilot, which extended Vafseo's availability to over 200,000 patients. Despite operational challenges, such as aligning logistics for home delivery and improving patient adherence, Akebia is working swiftly with dialysis providers to overcome these hurdles. The quarter also saw Vafseo's Win-Odds analysis from the INNO2VATE trial presented, showing a lower risk of death or hospitalization compared to ESA control, which the company expects will drive future prescribing growth. Financially, Akebia reported total revenues of $58.8 million, a significant increase from $37.4 million in the same period last year, and achieved a net income of approximately $540,000.

Vafseo Prescription Milestone

Vafseo has generated more total prescriptions in the first 41 weeks of launch than any recent launch in dialysis, reflecting strong reception from the dialysis community.

Significant Increase in Patient Access

Accessible patients increased from 40,000 in the first half of the year to almost 70,000 by the end of Q3, with further expansion expected with DaVita and other providers.

Revenue Growth

Total revenues increased to $58.8 million in Q3 2025 from $37.4 million in Q3 2024, with net product revenues rising to $56.8 million from $35.6 million.

Positive Financial Performance

Reported a net income of approximately $540,000 in Q3 2025 compared to a net loss of $20 million in Q3 2024, driven by increased net product revenues.

Akebia Therapeutics (AKBA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AKBA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 12, 2026	2025 (Q4)	>-0.01 / -	-0.1	―	―	―
Nov 10, 2025	2025 (Q3)	-0.01 / 0.00	-0.1	―	―
Aug 07, 2025	2025 (Q2)	-0.01 / 0.00	-0.04	―	―
May 08, 2025	2025 (Q1)	-0.04 / 0.03	-0.09	133.33% (+0.12)	―
Mar 13, 2025	2024 (Q4)	-0.08 / -0.10	0	―	―
Nov 07, 2024	2024 (Q3)	-0.06 / -0.10	-0.08	-25.00% (-0.02)	―
Aug 08, 2024	2024 (Q2)	-0.07 / -0.04	-0.06	33.33% (+0.02)	―
May 09, 2024	2024 (Q1)	-0.07 / -0.09	-0.14	35.71% (+0.05)	―
Mar 14, 2024	2023 (Q4)	-0.04 / 0.00	-0.04	―	―	―
Nov 08, 2023	2023 (Q3)	-0.09 / -0.08	-0.28	71.43% (+0.20)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AKBA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 10, 2025	$2.04	$1.67	-18.14%
Aug 07, 2025	$3.78	$3.01	-20.37%
May 08, 2025	$2.46	$2.62	+6.50%
Mar 13, 2025	$1.93	$1.69	-12.44%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Akebia Therapeutics (AKBA) report earnings?

Akebia Therapeutics (AKBA) is schdueled to report earning on Mar 12, 2026, After Close (Confirmed).

What is Akebia Therapeutics (AKBA) earnings time?

Akebia Therapeutics (AKBA) earnings time is at Mar 12, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AKBA EPS forecast?

AKBA EPS forecast for the fiscal quarter 2025 (Q4) is >-0.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing